Amylyx Pharmaceuticals (AMLX) News
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.02-0.18 (-0.69%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMLX news summary
We found 6 recent headlines mentioning Amylyx Pharmaceuticals (AMLX): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire, Seeking Alpha. For price context, AMLX is down 0.69% at $26.02. The most recent story, "Amylyx's Avexitide Cuts Low Blood Sugar Events By 55% In Phase 3 Trial; FDA Filing Due Year-End", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Amylyx Pharmaceuticals headlines
- Amylyx's Avexitide Cuts Low Blood Sugar Events By 55% In Phase 3 Trial; FDA Filing Due Year-End(RTTNews) - On Saturday, Amylyx Pharmaceuticals, Inc. (AMLX) said its investigational avexitide reduced low blood sugar events by 55% versus placebo in the Phase 3 LUCIDITY trial, meeting the primary…NasdaqAMLX, BRK.A
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsAmylyx Pharmaceuticals, Inc. reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in participants with post-bariatric hypoglycemia. The trial met the prespecified…NasdaqAMLX, LEN.B
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Amylyx Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026Business Wire
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearVertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.NasdaqVRTX, AMLX, BBIO, PRAX